key: cord-0783415-5dbsdhrr authors: Ayoub, H. H.; Mumtaz, G. R.; Seedat, S.; Makhoul, M.; Chemaitelly, H.; Abu-Raddad, L. J. title: Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates date: 2021-01-26 journal: nan DOI: 10.1101/2021.01.24.21250396 sha: 983933c924b0a86d02fb8f3e50cbbd8de00d68a5 doc_id: 783415 cord_uid: 5dbsdhrr We aimed to estimate, albeit crudely and provisionally, national, regional, and global proportions of respective populations that have been infected with SARS-CoV-2, and to assess infection morbidity and mortality rates, factoring both documented and undocumented infections. The estimates were generated by applying mathematical models to 159 countries and territories. The percentage of the world population that has been infected as of 31 December 2020 was estimated at 12.56% (95% CI: 11.17-14.05%). It was lowest in the Western Pacific Region at 0.66% (95% CI: 0.59-0.75%) and highest in the Americas at 41.92% (95% CI: 37.95-46.09%). The global infection fatality rate was 10.73 (95% CI: 10.21-11.29) per 10,000 infections. Globally per 1,000 infections, the infection acute-care bed hospitalization rate was 19.22 (95% CI: 18.73-19.51), the infection ICU bed hospitalization rate was 4.14 (95% CI: 4.10-4.18), the infection severity rate was 6.27 (95% CI: 6.18-6.37), and the infection criticality rate was 2.26 (95% CI: 2.24-2.28). If left unchecked with no interventions, the pandemic would eventually cause 8.18 million (95% CI: 7.30-9.18) deaths, 163.67 million (95% CI: 148.12-179.51) acute-care hospitalizations, 33.01 million (95% CI: 30.52-35.70) ICU hospitalizations, 50.23 million (95% CI: 46.24-54.67) severe cases, and 17.62 million (95% CI: 16.36-18.97) critical cases. The global population remains far below the herd immunity threshold and at risk of repeated waves of infection. Global epidemiology reveals immense regional variation in infection exposure and morbidity and mortality rates. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to be a global health challenge with profound adverse consequences for human health, societies, and Infections include documented cases involving laboratory-confirmed diagnosis and undocumented asymptomatic or mild cases. While a growing number of serological surveys are being conducted to answer this question [2] [3] [4] [5] [6] [7] [8] [9] [10] , the scope, scale, and geographic coverage of such studies remain limited. 2. "What are the true national and global COVID-19 morbidity and mortality rates, that is factoring all documented and undocumented infections?" The overall (total population) infection acute-care and ICU hospitalization rates, infection severity and criticality rates, and infection fatality rate were estimated for each country by applying the recently estimated age-stratified rates for these outcomes [12] to the population age-structure of each country. Age-stratified rates were based on a detailed analysis of the epidemic in Qatar [12] using data from a series of serological surveys [8] [9] [10] and extensive timeseries and age-stratified data for PCR laboratory-confirmed infections, PCR testing positivity rate, antibody testing positivity rate, PCR surveys, daily hospital admissions in acute-care and ICU beds, hospital occupancy in acute-care and ICU beds, incidence of severe and critical infections, as per WHO classifications [13] , and COVID-19 deaths as per WHO guidelines [14] . Qatar has one of the world's most extensive databases to document this epidemic and its toll at the national level [15] , such that Qatar's epidemic has been one of the most thoroughly investigated and best characterized [8] [9] [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] . It is presently unknown whether the infection morbidity and mortality rates for each age group (not for the total population) vary considerably from one country to another. These rates probably reflect primarily the basic biology of this infection more than the COVID-19 response or other factors in each country or population. The aim of the present study is to provide crude estimates for these rates in the total population of each country by factoring the population age structure, given the prominent role of age in the epidemiology of this pandemic [22] [23] [24] [25] , while future studies investigate and elaborate possible variations in these rates across different countries and populations. Infection morbidity and mortality rates were estimated for each country and territory with a population size >1 million, as of 2020. In total, estimates were generated for 159 countries and territories, virtually covering the world population [26] . Population sizes and demographic age-structures were extracted from the United Nations World Population Prospects database [26] . In each setting, rates were derived by weighting each rate in each age group by the proportion of the population in that age group, and then summing the contributions of all age groups. Two methods were used to derive the proportion of the population infected in each country and the average incidence rate since onset of the epidemic as of the end of 2020. The final estimate for each of these measures was based on the average of the estimates of both methods, to minimize the effect of potential bias inherent in each method. The first method was based on the reported number of COVID-19 deaths in each country, as per the WHO COVID-19 Dashboard [27] . The proportion of the population infected, irrespective of whether the infection was documented or undocumented, was estimated using the following expressions: Total population size = Infection fatality rate Highest HAQ Index globaly Since COVID-19 mortality may be affected by access to and quality of healthcare, with higher mortality for inferior access and quality, this method adjusts for these factors by utilizing the Global Burden of Disease study's Healthcare Access and Quality (HAQ) Index for each country and territory [28] . The HAQ Index provides a score ranging between 0-100 [28]. The above expressions still require adjustment for the average time delay between onset of infection and COVID-19 death, estimated from studies in different countries at about 20 days All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The infection detection rate is defined as the proportion of all infections that were actually diagnosed and laboratory-confirmed. Serological surveys and extensive analyses have shown that only about one in every ten actual infections is ever diagnosed [2] [3] [4] [5] [6] [7] [8] [9] [10] . Given the quality estimate for the infection detection rate in the well-characterized epidemic of Qatar, based on a series of serological surveys [8] [9] [10] and analyses of national databases, a value of 11.1% (95% uncertainty interval: 10.8-11.3%) was assumed for the infection detection rate [11, 12] . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The various estimated outcome measures for each country and territory are listed in Tables S1-S6 in the Supporting Information. An overview of results by WHO region and globally is provided below. The estimated infection acute-care bed hospitalization rate, infection ICU bed hospitalization rate, infection severity rate, and infection criticality rate were lowest in AFRO and highest in EURO, with substantial variation across regions ( Figure 2 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint AMRO at 131.7 (95% CI: 113.6-154.2) ( Figure 4B ). Globally, the averaged incidence rate was 35.4 (95% CI: 30.5-41.4) per 10,000 person-weeks. The estimated percentage of the population infected by the end of 2020, across WHO regions and globally was also higher using the reported deaths method than using the reported cases method, for all regions except SEARO ( Figure 5A ). The averaged percentage of the population infected was lowest in WPRO at 0.66% (95% CI: 0.59-0.75%), followed by AFRO at 3.25% (95% CI: 2.75-3.84%), SEARO at 8.11% (95% CI: 7.05-9.24%), EMRO at 13.67% (95% CI: 11.83-15.75%), EURO at 25.48% (95% CI: 22.76-28.40%), and highest in AMRO at 41.91% (95% CI: 37.95-46.09%) ( Figure 5B ). Globally, the averaged percentage of the population infected was estimated at 12.56% (95% CI: 11.17-14.05%). As of December 31, 2020, 1.79 million COVID-19 deaths had been reported, but the percentage of the global population infected was estimated at only 12.56% (95% CI: 11.17-14.05%). If the global population is to reach herd immunity with no vaccination, conservatively estimated at 60-70% infection exposure [ All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint The above results suggest that only 13% of the world's population has been infected by SARS-CoV-2, even though an entire year has already passed since the epidemic emerged in Wuhan, Hubei Province, China, in December, 2019 [37, 38] . This demonstrates that the overall global population remains far below the herd immunity threshold, estimated at 60-70% infection exposure (if not more for the mutant viral strains) [10, 35, 36] , and is still at risk of repeated epidemic waves of infection, with all that entails in terms of disease burden and social and economic disruption. This finding highlights the urgent need to accelerate COVID-19 vaccination to avert global expansion of this infection. Though overall exposure to this infection remains relatively low, there are immense variations by region and country, and the Americas appear to have already reached ~40% exposure, over 60fold higher than the Western Pacific Region (<1%). The average incidence rate experienced since epidemic onset varies similarly and is highest in the Americas, at 132 per 10,000 personweeks and lowest in the Western Pacific Region at only 1 per 10,000 person-weeks. These findings demonstrate strikingly high variability in the intensity of national epidemics during the first year since this infection's introduction. It remains to be seen whether this variability reflects different national responses to the epidemics, and/or clinical or biological cofactors that make some populations more affected than others. Even though the same age-stratified infection morbidity and mortality rates were used in generating estimates for all countries, total-population morbidity and mortality rates varied hugely among countries and by region, only because of differences in population age structures. For instance, the infection fatality rate in the European Region of 20 per 10,000 infections was nearly 6-fold higher than that in the African Region at <4 per 10,000 infections. Similarly, infection hospitalization and severity rates varied enormously. These findings may explain All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint apparent variability in the severity of this infection across countries and regions, and suggest that the disease burden could be substantially lower in countries with younger demographics, such as the African or Eastern Mediterranean Regions, as suggested earlier [23] . Notwithstanding this global variability, the above results corroborate the vast disease burden that this infection can cause. Nearly two million deaths have been confirmed worldwide as of December 31, 2020 [27], though only 13% of the global population has been infected. If we were to adopt today a herd immunity approach to dealing with this pandemic worldwide, that is, achieving the herd immunity threshold without vaccination, the pandemic would cause a total of 8 million COVID-19 deaths, 68 million COVID-19 severe and critical disease cases, and 197 million hospitalizations. These findings affirm the wisdom of epidemic suppression approaches adopted in most countries to tackle their respective epidemics [39] . Despite the high potential disease burden, the above-estimated infection morbidity and mortality rates are still substantially lower than those estimated earlier in the epidemic [6, [40] [41] [42] [43] [44] . Globally, out of every 10,000 infections, only 11 would result in COVID-19 deaths. Out of every 1,000 infections, only 6 would be severe and only 2 would be critical per WHO classification [13] . Nineteen would be hospitalized in an acute-care bed and 4 in an ICU bed. This study has limitations. In essence, it was based on age-stratified infection morbidity and mortality rates and the infection detection rate, estimated for a well-characterized and thoroughly investigated national epidemic, in which about half the population has already been infected [8] [9] [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] . While the epidemic of Qatar is perhaps the world's most advanced SARS-CoV-2 epidemic [8] [9] [10] [11] [12] [15] [16] [17] [18] [19] [20] [21] , the extent to which fundamental infection metrics estimated with precision for one country, even if they are primarily determined by the basic biology of this infection, can be extrapolated to other countries, remains unknown. It is reasonable that these All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint metrics could be affected by myriad factors, such as clinical or biological variations in human populations and circulating viral strains, the nature of COVID-19 responses, coverage of SARS-CoV-2 testing, and quality of reporting of cases and deaths. For instance, infection exposure is likely overestimated for countries with higher testing coverage and underestimated for countries with lower coverage. However, to make these estimates as realistic as possible, we used two independent methods with different input data to estimate infection exposure, to minimize the effect of any potential bias in either method or its data input. We also adjusted estimates for variation in healthcare access and quality by utilizing the Global Burden of Disease study's Healthcare Access and Quality Index for each country [28] . Still, the provided estimates should be seen as provisional, crude estimates for the purpose of providing a broad understanding of the global epidemiology of this infection and to guide the global COVID-19 response. Only 13% of the global population has been infected with SARS-CoV-2 suggesting that the world's population remains far below the herd immunity threshold and at risk of repeated epidemic waves of infection. Nevertheless, global epidemiology demonstrates immense regional variation in both infection exposure and SARS-CoV-2 morbidity and mortality rates. While the pandemic's expansion in nations with young populations could lead to a relatively milder disease burden than current expectations, this infection has the potential to cause nearly ten million COVID-19 deaths and 200 million hospitalizations worldwide, if its transmission is left unchecked and vaccination scale-up continues to lag far behind global needs. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We declare no competing interests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint (Figure 1) . Classification of infection severity and criticality was per WHO infection severity criteria [13]. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint (Figure 1 ). Classification of COVID-19 mortality was per WHO criteria [14] . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint Estimated average infection incidence rates since epidemic onset using the reported COVID-19 deaths method and using the reported COVID-19 cases method. B) Estimated infection incidence rates as averaged over the two methods. WHO regions include the African Region (AFRO), the Eastern Mediterranean Region (EMRO), the South-East Asia Region (SEARO), the Region of the Americas (AMRO), the Western Pacific Region (WPRO), and the European Region (EURO) (Figure 1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint A) Estimated percentages of populations infected using the reported COVID-19 deaths method and the reported COVID-19 cases method. B) Estimated percentages of the population infected as averaged over the two methods. WHO regions include the African Region (AFRO), the Eastern Mediterranean Region (EMRO), the South-East Asia Region (SEARO), the Region of the Americas (AMRO), the Western Pacific Region (WPRO), and the European Region (EURO) (Figure 1 ). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 26, 2021. ; https://doi.org/10.1101/2021.01.24.21250396 doi: medRxiv preprint Estimates for the global SARS-CoV-2 infection exposure and infection morbidity and mortality rates All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table S1 : Estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at least one million [1] in the WHO African Region (AFRO). Classification of infection severity and criticality was per WHO infection severity classifications [2] . Classification of COVID-19 death was also per WHO guidelines [3] . [4] . c The estimate for the incidence rate was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. d The estimate for the proportion of the population infected was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. [2] . Classification of COVID-19 death was also per WHO guidelines [3] . [4] . c The estimate for the incidence rate was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. d The estimate for the proportion of the population infected was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. Table S3 : Estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at least one million [1] in the WHO Eastern Mediterranean Region (EMRO). Classification of infection severity and criticality was per WHO infection severity classifications [2] . Classification of COVID-19 death was also per WHO guidelines [3] . [4] . c The estimate for the incidence rate was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. d The estimate for the proportion of the population infected was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. Table S5 : Estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at least one million [1] in the WHO South-East Asia Region (SEARO). Classification of infection severity and criticality was per WHO infection severity classifications [2] . Classification of COVID-19 death was also per WHO guidelines [3] . [4] . c The estimate for the incidence rate was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. d The estimate for the proportion of the population infected was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. e No reported COVID-19 cases and deaths. Table S6 : Estimates for key SARS-CoV-2 epidemiologic indicators for countries and territories with a population of at least one million [1] in the WHO Western Pacific Region (WPRO). Classification of infection severity and criticality was per WHO infection severity classifications [2] . Classification of COVID-19 death was also per WHO guidelines [3] . [4] . c The estimate for the incidence rate was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. d The estimate for the proportion of the population infected was based on the average of the two estimates generated by the reported COVID-19 deaths method and the reported COVID-19 cases method. Prevalence of SARS-CoV-2 antibodies in a large nationwide sample of patients on dialysis in the USA: a cross-sectional study Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States Substantial underestimation of SARS-CoV-2 infection in the United States SEROCoV-POP): a population-based study The infection fatality rate of COVID-19 inferred from seroprevalence data Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers Seroprevalence of SARS-CoV-2 infection in the craft and manual worker population of Qatar SARS-CoV-2 seroprevalence in the urban population of Qatar: An analysis of antibody testing on a sample of 112 Evidence for and level of herd immunity against SARS-CoV-2 infection: the ten-community study Mathematical modeling of the SARS-CoV-2 epidemic in Qatar and its impact on the national response to COVID-19 SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates. medRxiv 2020.11.29.20240416 (non-peer-reviewed preprint), 2020. 13. World Health Organization, Clinical management of COVID-19 World Health Organization, International guidelines for certification and classification (coding) of COVID-19 as cause of death Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months Assessment of the risk of SARS-CoV-2 reinfection in an intense reexposure setting Epidemiological investigation of the first 5685 cases of SARS-CoV-2 infection in Qatar Epidemiological impact of prioritizing SARS-CoV-2 vaccination by antibody status: Mathematical modeling analyses Armenia 2,963 United Nations Department of Economic and Social Affairs Population Dynamics, The 2019 Revision of World Population Prospects World Health Organization, Clinical management of COVID-19 World Health Organization, International guidelines for certification and classification (coding) of COVID-19 as cause of death Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study The authors are also grateful for support provided by the Biomedical Research Program and the Biostatistics, Epidemiology, and Biomathematics Research Core at Weill Cornell Medicine-Qatar. Developed mathematical models were made possible by NPRP grant number 9-040-3-008 and NPRP grant number 12S-0216-190094 from the Qatar National Research Fund (a member of